MDACC Study No:2011-0192 ( NCT No: NCT01440582)
Title:Phase I/Ib Trial of the Efficacy and Safety of combination therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in transplant eligible patients with newly diagnosed Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:Acyclovir; Aspirin; Bortezomib; Dexamethasone; Lenalidomide; Panobinostat
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the drug panobinostat that can be given in combination with the drugs
Velcade (bortezomib), Revlimid (lenalidomide), and Decadron (dexamethasone) to
patients with MM. The safety of this drug combination will also be studied.

Panobinostat is designed to cause chemical changes in different groups of
proteins that are attached to DNA (the genetic material of cells), which may
slow the growth of cancer cells or cause the cancer cells to die.

Bortezomib is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.

Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may slow the growth of cancer cells.

Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:Acyclovir
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults